EUVIMEDEUVIMED entdecken
Multizentrische StudieVergleichsstudieKohortenstudieOpen Access · CC BY-NC-ND 4.0

Video-Assisted Thoracoscopic Surgery Versus Thoracotomy Following Neoadjuvant Immunochemotherapy in Resectable Stage III Non-Small Cell Lung Cancer Among Chinese Populations: A Multi-Center Retrospective Cohort Study

Hanbo Pan, Hang Chen, Weicheng Kong, Junwei Ning, Zhen Ge, Yu Tian, Ningyuan Zou, Hongda Zhu, Jiaqi Zhang, Yixing Tao, Zenan Gu, Min Zheng und 7 weitere

Clinical Lung Cancer · 2024

DOI: 10.1016/j.cllc.2024.03.008 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Lung Cancer, 2024. Verfasst von Hanbo Pan und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgical Oncology, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Sha…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoadjuvant Therapy, Neoplasm Staging. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Immune checkpoint inhibitors have revolutionized non-small cell lung cancer (NSCLC) treatment but may pose greater technical challenges for surgery. This study aims to assess the feasibility and oncological effectiveness of video-assisted thoracoscopic surgery (VATS) for resectable stage III NSCLC after neoadjuvant immunochemotherapy. METHODS: Initial stage IIIA-IIIB NSCLC patients with neoadjuvant immunochemotherapy undergoing either VATS or open lobectomy at 6 medical centers during 2019-2023 were retrospectively identified. Perioperative outcomes and 2-year survival was analyzed. Propensity-score matching (PSM) was employed to balance patient baseline characteristics. RESULTS: Among the total 143 patients, PSM yielded 62 cases each for VATS and OPEN groups. Induction-related adverse events were comparable between the 2 groups. VATS showed a 14.5% conversion rate. Notably, VATS decreased numeric rating scales for postoperative pain, shortened chest tube duration (5[4-7] vs. 6[5-8] days, P = .021), reduced postoperative comorbidities (21.0% vs. 37.1%, P = .048), and dissected less N1 lymph nodes (5[4-6] vs. 7[5-9], P = .005) compared with thoracotomy. Even when converted, VATS achieves perioperative outcomes equivalent to thoracotomy. Additionally, over a median follow-up of 29.5 months, VATS and thoracotomy demonstrated comparable 2-year recurrence-free survival (77.20% vs. 73.73%, P = .640), overall survival (87.22% vs. 88.00%, P = .738), cumulative incidences of cancer-related death, and recurrence patterns. Subsequent subgroup comparisons and multivariate Cox analysis likewise revealed no statistical difference between VATS and thoracotomy. CONCLUSION: VATS is a viable and effective option for resectable stage III NSCLC patients following neoadjuvant immunochemotherapy, leading to decreased surgical-related pain, earlier chest tube removal, reduced postoperative complications, and similar survival outcomes compared to thoracotomy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsNeoadjuvant TherapyNeoplasm StagingThoracic Surgery, Video-AssistedThoracotomyAgedFemaleHumansMaleMiddle AgedChinaEast Asian PeopleFollow-Up StudiesImmunotherapyPneumonectomyRetrospective StudiesSurvival Rate

Stichwörter der Autor:innen

Immune checkpoint inhibitorsLobectomyMinimally Invasive surgeryPerioperative outcomesSurvival

Autor:innen und Institutionen

  • Department of Thoracic Surgical Oncology, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Cardiothoracic Surgery, The Affiliated Lihuili Hospital of Ningbo University, Ningbo, China.
  • Department of Thoracic Surgery, Putuo District People's Hospital, Zhoushan, China.
  • Department of Thoracic Surgery, Shanghai Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Cardiothoracic Surgery, The First Affiliated Hospital of Ningbo University, Ningbo, China.
  • Department of Clinical Medicine, Wenzhou People's Hospital, Shanghai University School of Medicine, Wenzhou, China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Pan, H., Chen, H., Kong, W., Ning, J., Ge, Z., Tian, Y., Zou, N., Zhu, H., Zhang, J., Tao, Y., Gu, Z., Zheng, M., Ruan, G., Jiang, L., Li, Z., Huang, J., Zhou, C., Xu, G., & Luo, Q. (2024). Video-Assisted Thoracoscopic Surgery Versus Thoracotomy Following Neoadjuvant Immunochemotherapy in Resectable Stage III Non-Small Cell Lung Cancer Among Chinese Populations: A Multi-Center Retrospective Cohort Study. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2024.03.008

Vancouver

Pan H, Chen H, Kong W, Ning J, Ge Z, Tian Y, et al. Video-Assisted Thoracoscopic Surgery Versus Thoracotomy Following Neoadjuvant Immunochemotherapy in Resectable Stage III Non-Small Cell Lung Cancer Among Chinese Populations: A Multi-Center Retrospective Cohort Study. Clinical Lung Cancer. 2024. doi:10.1016/j.cllc.2024.03.008

BibTeX
@article{Pan2024,
  author = {Pan, Hanbo and Chen, Hang and Kong, Weicheng and Ning, Junwei and Ge, Zhen and Tian, Yu and Zou, Ningyuan and Zhu, Hongda and Zhang, Jiaqi and Tao, Yixing and Gu, Zenan and Zheng, Min and Ruan, Guomo and Jiang, Long and Li, Ziming and Huang, Jia and Zhou, Chengwei and Xu, Guodong and Luo, Qingquan},
  title = {Video-Assisted Thoracoscopic Surgery Versus Thoracotomy Following Neoadjuvant Immunochemotherapy in Resectable Stage III Non-Small Cell Lung Cancer Among Chinese Populations: A Multi-Center Retrospective Cohort Study},
  journal = {Clinical Lung Cancer},
  year = {2024},
  doi = {10.1016/j.cllc.2024.03.008}
}
Kostenlos starten →